Friday, January 23, 2026

Ventripoint Installs Whole Heart Analysis System At Toronto General Hospital

Ventripoint Diagnostics (TSXV: VPT) has seen its technology installed at the largest cardiac centre in Canada. The company announced this morning that its VMS+3.0 whole heart analysis system has seen its first install at the Peter Munk Cardiac Center in Toronto, Canada.

The Peter Munk Cardiac Centre resides at the University Hospital Network’s Toronto General Hospital. The addition of the device enables the Centre to be able to assess heart function in all four chambers of the heart via an echocardiogram, rather than that of an MRI. The technology enables the Hospital to manage and conduct future research in patients with right heart failure.

Commenting on the installation of the system, Executive Chairman of Ventripoint Dr George Adams stated, “just as it is PMCC’s mission to use the best equipment to optimize patient care, it has always been the Company’s mission to create “best-in-breed” equipment to assist clinicians and medical personnel in a myriad of clinical settings to accurately assess heart function. We feel incredibly privileged to have this world-leading hospital adopt our system.”

The install marks the third install at a top-tier hospital in the last five weeks, while also being the fifth hospital in Canada to install the new VMS+3.0 system. Previously, the company installed a system at the Erasmus-Sophia University Medical Center in the Netherlands, one of the leading cardiac centres in Europe, as well as at the University of Texas MD Anderson Cancer Center, one of the worlds most respected cancer centres.

To date, a total of 10 VMS+3.0 systems have been delivered, with the company expecting to install units in additional leading cardiac centres before the end of the year.

Ventripoint Diagnostics last traded at $0.10 on the TSX Venture.


FULL DISCLOSURE: Ventripoint Diagnostics is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Ventripoint Diagnostics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Moon River Moly: The Davidson Moly-Copper-Tungsten PEA

Integra: The DeLamar Heap Leach Feasibility Study

Highlander Silver: The Saviour Of Bear Creek Mining

Recommended

Steadright Subsidiary NSM Capital Sarl Applies For License At Titanbeach One

Goliath Resources Accelerates Option Agreement On Golddigger While Reducing NSR

Related News

Ventripoint Receives Further Funding From National Research Council of Canada

Ventripoint Diagnostics (TSXV: VPT) this morning had a brief release, indicating the firm has received...

Monday, December 6, 2021, 08:14:58 AM

Ventripoint Installs First VMS+3.0 At Renowned US Cancer Hospital

Ventripoint Diagnostics (TSXV: VPT) this morning announced that it has installed its first VMS+3.0 whole-heart...

Thursday, October 8, 2020, 09:36:33 AM

Ventripoint Files For Provisional Patent On Heart Motion Tracking Tech

Ventripoint Diagnostics (TSXV: VPT) is evidently looking to grow its portfolio of intellectual property. The...

Monday, April 19, 2021, 09:44:24 AM

Ventripoint Enters Collaboration Agreement To Test Echocardiology Technology For Use With Canines

Ventripoint Diagnostics (TSXV: VPT) has entered into a new collaboration agreement as of this morning....

Monday, January 11, 2021, 09:21:12 AM

Ventripoint Diagnostics: Using AI To Analyze The Heart – The Daily Dive feat George Adams

Today on the Daily Dive, our host Cassandra Leah sits down with George Adams, Executive...

Wednesday, April 21, 2021, 01:30:00 PM